{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:14:51Z","timestamp":1778606091255,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022MH216"],"award-info":[{"award-number":["ZR2022MH216"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20421"],"award-info":[{"award-number":["U23A20421"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00406-024-01809-9","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T03:01:55Z","timestamp":1714014115000},"page":"1301-1316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023"],"prefix":"10.1007","volume":"275","author":[{"given":"Li-yuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-fen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-jie","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-0439","authenticated-orcid":false,"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"issue":"3","key":"1809_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/jama.292.3.338","volume":"292","author":"H Jick","year":"2004","unstructured":"Jick H, Kaye JA, Jick SS (2004) Antidepressants and the risk of suicidal behaviors. JAMA 292(3):338\u2013343. https:\/\/doi.org\/10.1001\/jama.292.3.338","journal-title":"JAMA"},{"issue":"10","key":"1809_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/pcn.12902","volume":"73","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry Clin Neurosci 73(10):613\u2013627. https:\/\/doi.org\/10.1111\/pcn.12902","journal-title":"Psychiatry Clin Neurosci"},{"key":"1809_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113935","volume":"177","author":"K Hashimoto","year":"2020","unstructured":"Hashimoto K (2020) Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol 177:113935. https:\/\/doi.org\/10.1016\/j.bcp.2020.113935","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"1809_CR4","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1038\/s41380-022-01587-7","volume":"27","author":"K Hashimoto","year":"2022","unstructured":"Hashimoto K (2022) (2022) Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic? Mol Psychiatry 27(8):3116\u20133118. https:\/\/doi.org\/10.1038\/s41380-022-01587-7","journal-title":"Mol Psychiatry"},{"key":"1809_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108431","volume":"246","author":"JN Johnston","year":"2023","unstructured":"Johnston JN, Henter ID, Zarate CA (2023) The antidepressant actions of ketamine and its enantiomers. Pharmacol Ther 246:108431. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108431","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1809_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351\u2013354. https:\/\/doi.org\/10.1016\/s0006-3223(99)00230-9","journal-title":"Biol Psychiatry"},{"key":"1809_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS (2006) Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856\u2013864. https:\/\/doi.org\/10.1001\/archpsyc.63.8.856","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"1809_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","volume":"80","author":"JB Singh","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly E, Xi LW, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, Van Nueten L (2016) Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80(6):424\u2013431. https:\/\/doi.org\/10.1016\/j.biopsych.2015.10.018","journal-title":"Biol Psychiatry"},{"issue":"13","key":"1809_CR9","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/npp.2017.94","volume":"42","author":"TP Su","year":"2017","unstructured":"Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, Tu PC, Bai YM, Cheng CM, Krystal JH (2017) Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology 42(13):2482\u20132492. https:\/\/doi.org\/10.1038\/npp.2017.94","journal-title":"Neuropsychopharmacology"},{"key":"1809_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB (2019) Efficacy and safety of flexibly dosed Esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 176:428\u2013438. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19020172","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1809_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","volume":"271","author":"GC Leal","year":"2021","unstructured":"Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda ALT, Quarantini LC (2021) Eur Arch Psychiatry Clin Neurosci 271(3):577\u2013582. https:\/\/doi.org\/10.1007\/s00406-020-01110-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1809_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould TD (2018) Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 23:801\u2013811. https:\/\/doi.org\/10.1038\/mp.2017.255","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1809_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","volume":"83","author":"C Yang","year":"2018","unstructured":"Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, Hashimoto K (2018) Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry 83(1):18\u201328. https:\/\/doi.org\/10.1016\/j.biopsych.2017.05.016","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1809_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","volume":"9","author":"C Yang","year":"2019","unstructured":"Yang C, Yang J, Luo A, Hashimoto K (2019) Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry 9(1):280. https:\/\/doi.org\/10.1038\/s41398-019-0624-1","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1809_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41398-020-0733-x","volume":"10","author":"K Zhang","year":"2020","unstructured":"Zhang K, Yang C, Chang L, Sakamoto A, Suzuki T, Fujita Y, Qu Y, Wang S, Pu Y, Tan Y, Wang X, Ishima T, Shirayama Y, Hatano M, Tanaka KF, Hashimoto K (2020) Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21. Transl Psychiatry 10(1):32. https:\/\/doi.org\/10.1038\/s41398-020-0733-x","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1809_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","volume":"27","author":"Y Wei","year":"2022","unstructured":"Wei Y, Chang LJ, Hashimoto K (2022) Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry 27(1):559\u2013573. https:\/\/doi.org\/10.1038\/s41380-021-01121-1","journal-title":"Mol Psychiatry"},{"key":"1809_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109219","volume":"218","author":"JC Zhang","year":"2022","unstructured":"Zhang JC, Yao W, Hashimoto K (2022) Arketamine, a new rapid-acting antidepressant: a historical review and future directions. Neuropharmacology 218:109219. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109219","journal-title":"Neuropharmacology"},{"key":"1809_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109305","volume":"222","author":"K Zhang","year":"2023","unstructured":"Zhang K, Yao Y, Hashimoto K (2023) Ketamine and its metabolites: Potential as novel treatments for depression. Neuropharmacology 222:109305. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109305","journal-title":"Neuropharmacology"},{"issue":"3","key":"1809_CR19","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","volume":"27","author":"W Yao","year":"2022","unstructured":"Yao W, Cao Q, Luo S, He L, Yang C, Chen J, Qi Q, Hashimoto K, Zhang JC (2022) Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Mol Psychiatry 27(3):1618\u20131629. https:\/\/doi.org\/10.1038\/s41380-021-01377-7","journal-title":"Mol Psychiatry"},{"key":"1809_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02288-5","author":"C Huang","year":"2023","unstructured":"Huang C, Wu Z, Wang D, Qu Y, Zhang J, Jiang R, Xu X, Xu X, Wang Y, Liu H, He T, Liu C, Chen G, Yang JJ, Hashimoto K (2023) Myelin-associated oligodendrocytic basic protein-dependent myelin repair confers the long-lasting antidepressant effect of ketamine. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-023-02288-5","journal-title":"Mol Psychiatry"},{"key":"1809_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","volume":"116","author":"JC Zhang","year":"2014","unstructured":"Zhang JC, Li SX, Hashimoto K (2014) R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochemi Behav 116:137\u2013141. https:\/\/doi.org\/10.1016\/j.pbb.2013.11.033","journal-title":"Pharmacol Biochemi Behav"},{"issue":"9","key":"1809_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.136","volume":"5","author":"C Yang","year":"2015","unstructured":"Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5(9):e632. https:\/\/doi.org\/10.1038\/tp.2015.136","journal-title":"Transl Psychiatry"},{"key":"1809_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","volume":"181","author":"L Chang","year":"2019","unstructured":"Chang L, Zhang K, Pu Y, Qu Y, Wang S, Xiong Z, Ren Q, Dong C, Fujita Y, Hashimoto K (2019) Comparison of antidepressant and side effects in mice after intranasal administration of (R, S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav 181:53\u201359. https:\/\/doi.org\/10.1016\/j.pbb.2019.04.008","journal-title":"Pharmacol Biochem Behav"},{"key":"1809_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109207","volume":"218","author":"T He","year":"2022","unstructured":"He T, Wang D, Wu Z, Huang C, Xu X, Xu X, Liu C, Hashimoto K, Yang C (2022) A bibliometric analysis of research on (R)-ketamine from 2002 to 2021. Neuropharmacology 218:109207. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109207","journal-title":"Neuropharmacology"},{"issue":"10","key":"1809_CR25","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/biom12101464","volume":"12","author":"T He","year":"2022","unstructured":"He T, Wu Z, Zhang X, Liu H, Wang Y, Jiang R, Liu C, Hashimoto K, Yang C (2022) A bibliometric analysis of research on the role of BDNF in depression and treatment. Biomolecules 12(10):1464. https:\/\/doi.org\/10.3390\/biom12101464","journal-title":"Biomolecules"},{"key":"1809_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.839198","volume":"15","author":"H Miao","year":"2022","unstructured":"Miao H, Yu K, Gao D, Lin X, Cao Y, Liu X, Qiao H, Li T (2022) A bibliometric analysis of research on ketamine from 2001 to 2020. Front Mol Neurosci 15:839198. https:\/\/doi.org\/10.3389\/fnmol.2022.839198","journal-title":"Front Mol Neurosci"},{"key":"1809_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2022.103146","volume":"72","author":"S Grover","year":"2022","unstructured":"Grover S, Gupta BM (2022) Global research on Obsessive Compulsive Disorder and related disorders: A scientometric assessment of global research during 2002\u20132021. Asian J Psychiatry 72:103146. https:\/\/doi.org\/10.1016\/j.ajp.2022.103146","journal-title":"Asian J Psychiatry"},{"key":"1809_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2023.103561","volume":"83","author":"W Zhou","year":"2023","unstructured":"Zhou W, Bai X, Yang Y, Huang M, Zheng Q, Wu J, Wang R, Gan X (2023) Revelations of delirium subtype research: a bibliometric analysis of publications in the past twenty years in the field. Asian J Psychiatry 83:103561. https:\/\/doi.org\/10.1016\/j.ajp.2023.103561","journal-title":"Asian J Psychiatry"},{"issue":"2","key":"1809_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84(2):523\u2013538. https:\/\/doi.org\/10.1007\/s11192-009-0146-3","journal-title":"Scientometrics"},{"issue":"Suppl 1","key":"1809_CR30","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1073\/pnas.0307513100","volume":"101","author":"C Chen","year":"2004","unstructured":"Chen C (2004) Searching for intellectual turning points: progressive knowledge domain visualization. Proc Nat Acad Sci USA 101(Suppl 1):5303\u20135310. https:\/\/doi.org\/10.1073\/pnas.0307513100","journal-title":"Proc Nat Acad Sci USA"},{"issue":"3","key":"1809_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/asi.20317","volume":"57","author":"C Chen","year":"2006","unstructured":"Chen C (2006) CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inform Sci Technol 57(3):359\u2013377. https:\/\/doi.org\/10.1002\/asi.20317","journal-title":"J Am Soc Inform Sci Technol"},{"issue":"7604","key":"1809_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan PX, Pribut HJ, Singh NS, Dossou KSS, Fang YH, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533(7604):481\u2013486. https:\/\/doi.org\/10.1038\/nature17998","journal-title":"Nature"},{"issue":"7354","key":"1809_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475(7354):91\u201395. https:\/\/doi.org\/10.1038\/nature10130","journal-title":"Nature"},{"issue":"5994","key":"1809_CR34","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329(5994):959\u2013964. https:\/\/doi.org\/10.1126\/science.1190287","journal-title":"Science"},{"issue":"6103","key":"1809_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1126\/science.1222939","volume":"338","author":"RS Duman","year":"2012","unstructured":"Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338(6103):68\u201372. https:\/\/doi.org\/10.1126\/science.1222939","journal-title":"Science"},{"issue":"1","key":"1809_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2021.2022254","volume":"55","author":"A Hadar","year":"2023","unstructured":"Hadar A, David J, Shalit N, Roseman L, Gross R, Sessa B, Lev-Ran S (2023) The psychedelic renaissance in clinical research: A bibliometric analysis of three decades of human studies with psychedelics. J Psychoactive Drugs 55(1):1\u201310. https:\/\/doi.org\/10.1080\/02791072.2021.2022254","journal-title":"J Psychoactive Drugs"},{"key":"1809_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-024-01770-7","author":"K Hashimoto","year":"2024","unstructured":"Hashimoto K (2024) Are \u201cmystical experiences\u201d essential for antidepressant actions of ketamine and classic psychedelics? Eur Arch Psychiatry Clin Neurosci in press. https:\/\/doi.org\/10.1007\/s00406-024-01770-7","journal-title":"Eur Arch Psychiatry Clin Neurosci in press"},{"key":"1809_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euroneuro.2022.09.004","volume":"64","author":"M Solmi","year":"2022","unstructured":"Solmi M, Chen C, Daure C, Buot A, Ljuslin M, Verroust V, Mallet L, Khazaal Y, Rothen S, Thorens G, Zullino D, Gobbi G, Rosenblat J, Husain MI, De Gregorio D, Castle D, Sab\u00e9 M (2022) A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. Eur Neuropsychopharmacol 64:44\u201360. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.09.004","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"1809_CR39","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","volume":"113","author":"EF Domino","year":"2010","unstructured":"Domino EF (2010) Taming the ketamine tiger. Anesthesiology 113(3):678\u2013684. https:\/\/doi.org\/10.1097\/ALN.0b013e3181ed09a2","journal-title":"Anesthesiology"},{"issue":"8","key":"1809_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/archgenpsychiatry.2010.90","volume":"67","author":"N Diazgranados","year":"2010","unstructured":"Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67(8):93\u2013802. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.90","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"1809_CR41","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/npp.2011.338","volume":"37","author":"L Ibrahim","year":"2012","unstructured":"Ibrahim L, DiazGranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate CA (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37(6):1526\u20131533. https:\/\/doi.org\/10.1038\/npp.2011.338","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"1809_CR42","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","volume":"71","author":"CA Zarate","year":"2012","unstructured":"Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 71(11):939\u2013946. https:\/\/doi.org\/10.1016\/j.biopsych.2011.12.010","journal-title":"Biol Psychiatry"},{"issue":"2","key":"1809_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2009.02.010","volume":"123","author":"R Machado-Vieira","year":"2009","unstructured":"Machado-Vieira R, Salvadore G, DiazGranados N, Zarate CA (2009) Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123(2):143\u2013150. https:\/\/doi.org\/10.1016\/j.pharmthera.2009.02.010","journal-title":"Pharmacol Ther"},{"issue":"10","key":"1809_CR44","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.biopsych.2016.05.005","volume":"81","author":"MS Lener","year":"2017","unstructured":"Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, Zarate CA (2017) Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry 81(10):886\u2013897. https:\/\/doi.org\/10.1016\/j.biopsych.2016.05.005","journal-title":"Biol Psychiatry"},{"key":"1809_CR45","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","volume":"278","author":"A Bahji","year":"2021","unstructured":"Bahji A, Vazquez GH, Zarate CA (2021) Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord 278:542\u2013555. https:\/\/doi.org\/10.1016\/j.jad.2020.09.071","journal-title":"J Affect Disord"},{"issue":"1","key":"1809_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1124\/jpet.116.239228","volume":"361","author":"K Fukumoto","year":"2017","unstructured":"Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi J, Hashimoto K, Chaki S (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361(1):9\u201316. https:\/\/doi.org\/10.1124\/jpet.116.239228","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"1809_CR47","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","volume":"82","author":"C Yang","year":"2017","unstructured":"Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K (2017) (R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psychiatry 82(5):e43\u2013e44. https:\/\/doi.org\/10.1016\/j.biopsych.2016.12.020","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1809_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/ijnp\/pyx108","volume":"21","author":"Y Shirayama","year":"2018","unstructured":"Shirayama Y, Hashimoto K (2018) Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine. Int J Neuropsychopharmacol 21(1):84\u201388. https:\/\/doi.org\/10.1093\/ijnp\/pyx108","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"1809_CR49","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41386-018-0084-y","volume":"43","author":"JI Yamaguchi","year":"2018","unstructured":"Yamaguchi JI, Toki H, Qu Y, Yang C, Koike H, Hashimoto K, Mizuno-Yasuhira A, Chaki S (2018) (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Neuropsychopharmacology 43(9):1900\u20131907. https:\/\/doi.org\/10.1038\/s41386-018-0084-y","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1809_CR50","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1038\/s41598-018-22449-9","volume":"8","author":"K Zhang","year":"2018","unstructured":"Zhang K, Fujita Y, Hashimoto K (2018) Lack of metabolism in (R)-ketamine\u2019s antidepressant actions in a chronic social defeat stress model. Sci Rep 8(1):4007. https:\/\/doi.org\/10.1038\/s41598-018-22449-9","journal-title":"Sci Rep"},{"issue":"11","key":"1809_CR51","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1007\/s00213-018-5017-2","volume":"235","author":"K Zhang","year":"2018","unstructured":"Zhang K, Toki H, Fujita Y, Ma M, Chang L, Qu Y, Harada S, Nemoto T, Mizuno-Yasuhira A, Yamaguchi JI, Chaki S, Hashimoto K (2018) Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. Psychopharmacology 235(11):3177\u20133185. https:\/\/doi.org\/10.1007\/s00213-018-5017-2","journal-title":"Psychopharmacology"},{"issue":"9","key":"1809_CR52","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li HL, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB (2019) Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiat 76(9):893\u2013903. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1189","journal-title":"JAMA Psychiat"},{"issue":"12","key":"1809_CR53","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","volume":"6","author":"EH Turner","year":"2019","unstructured":"Turner EH (2019) Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry 6(12):977\u2013979. https:\/\/doi.org\/10.1016\/S2215-0366(19)30394-3","journal-title":"Lancet Psychiatry"},{"key":"1809_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01732-5","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Du Z, Shen Y, Zhou Q (2023) Zhu H (2023) The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-023-01732-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1809_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2021.110371","volume":"111","author":"A Camargo","year":"2021","unstructured":"Camargo A, Dalmagro AP, Wolin IAV, Siteneski A, Zeni ALB, Rodrigues ALS (2021) A low-dose combination of ketamine and guanosine counteracts corticosterone-induced depressive-like behavior and hippocampal synaptic impairments via mTORC1 signaling. Prog Neuropsychopharmacol Biol Psychiatry 111:110371. https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110371","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"1809_CR56","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/S0033291716000064","volume":"46","author":"T Kishimoto","year":"2016","unstructured":"Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU (2016) Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 46(7):1459\u20131472. https:\/\/doi.org\/10.1017\/S0033291716000064","journal-title":"Psychol Med"},{"issue":"4","key":"1809_CR57","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/npp.2015.233","volume":"41","author":"K Fukumoto","year":"2016","unstructured":"Fukumoto K, Iijima M, Chaki S (2016) The antidepressant effects of an mGlu2\/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN. Neuropsychopharmacology 41(4):1046\u20131056. https:\/\/doi.org\/10.1038\/npp.2015.233","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1809_CR58","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1172\/JCI130808","volume":"130","author":"DM Gerhard","year":"2020","unstructured":"Gerhard DM, Pothula S, Liu RJ, Wu M, Li XY, Girgenti MJ, Taylor SR, Duman CH, Delpire E, Picciotto M, Wohleb ES, Duman RS (2020) GABA interneurons are the cellular trigger for ketamine\u2019s rapid antidepressant actions. J Clin Invest 130(3):1336\u20131349. https:\/\/doi.org\/10.1172\/JCI130808","journal-title":"J Clin Invest"},{"key":"1809_CR59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pharmthera.2019.02.017","volume":"199","author":"TH Pham","year":"2019","unstructured":"Pham TH, Gardier AM (2019) Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacol Ther 199:58\u201390. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.02.017","journal-title":"Pharmacol Ther"},{"key":"1809_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2023.110910","volume":"129","author":"L Ren","year":"2024","unstructured":"Ren L (2024) The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways. Prog Neuro-Psychopharmacol Biol Psychiatry 129:110910. https:\/\/doi.org\/10.1016\/j.pnpbp.2023.110910","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"1809_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biopsych.2020.12.006","volume":"90","author":"R Shinohara","year":"2021","unstructured":"Shinohara R, Aghajanian GK, Abdallah CG (2021) Neurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities. Biol Psychiatry 90(2):85\u201395. https:\/\/doi.org\/10.1016\/j.biopsych.2020.12.006","journal-title":"Biol Psychiatry"},{"issue":"3","key":"1809_CR62","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA, Gould TD (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70(3):621\u2013660. https:\/\/doi.org\/10.1124\/pr.117.015198","journal-title":"Pharmacol Rev"},{"issue":"2","key":"1809_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00406-016-0718-1","volume":"267","author":"Y Shirayama","year":"2017","unstructured":"Shirayama Y, Hashimoto K (2017) Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci 267(2):177\u2013182. https:\/\/doi.org\/10.1007\/s00406-016-0718-1","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"9","key":"1809_CR64","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/mp.2015.176","volume":"21","author":"FR Carreno","year":"2016","unstructured":"Carreno FR, Donegan JJ, Boley AM, Shah A, DeGuzman M, Frazer A, Lodge DJ (2016) Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. Mol Psychiatry 21(9):1298\u20131308. https:\/\/doi.org\/10.1038\/mp.2015.176","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1809_CR65","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41398-022-01943-9","volume":"12","author":"S Deyama","year":"2022","unstructured":"Deyama S, Kondo M, Shimada S, Kaneda K (2022) IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine. Transl Psychiatry 12(1):178. https:\/\/doi.org\/10.1038\/s41398-022-01943-9","journal-title":"Transl Psychiatry"},{"issue":"7984","key":"1809_CR66","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41586-023-06624-1","volume":"622","author":"S Ma","year":"2023","unstructured":"Ma S, Chen M, Jiang Y, Xiang X, Wang S, Wu Z, Li S, Cui Y, Wang J, ZhuY ZY, Ma H, Duan S, Li H, Yang Y, Lingle CJ, Hu H (2023) Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb. Nature 622(7984):802\u2013809. https:\/\/doi.org\/10.1038\/s41586-023-06624-1","journal-title":"Nature"},{"issue":"7692","key":"1809_CR67","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature25509","volume":"554","author":"Y Yang","year":"2018","unstructured":"Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, Hu H (2018) Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature 554(7692):317\u2013322. https:\/\/doi.org\/10.1038\/nature25509","journal-title":"Nature"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01809-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-024-01809-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01809-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:05:04Z","timestamp":1752764704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-024-01809-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1809"],"URL":"https:\/\/doi.org\/10.1007\/s00406-024-01809-9","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Hashimoto is the inventor of filed patent applications on \u201cThe use of R-Ketamine in the treatment of psychiatric diseases\u201d, \u201c(S)-norketamine and salt thereof as pharmaceutical\u201d, \u201cR-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder\u201d, \u201cPreventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases\u201d, and \u201cR-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder\u201d by the Chiba University. Dr. Hashimoto has also received speakers\u2019 honoraria, consultant fee, or research support from Abbott, Boehringer-Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. Dr. Hashimoto is Editor at European Archives of Psychiatry and Clinical Neuroscience.\u00a0Other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}